HYBRID EVENT: You can participate in person at Rome, Italy or Virtually from your home or work.

2nd Edition of International Conference

and Expo on Clinical Microbiology

June 23-24, 2023 | Rome, Italy

ICCM 2022

Jawad Alzeer

Speaker at Clinical Microbiology 2022 - Jawad Alzeer
University of Zurich, Switzerland
Title : Reduction of viral resistance and activation of the immune system through implementation of the LeChatelier principle


Attempts to improve prevention and develop cures are highly appreciated. Indeed, many approaches and models to prevent and cure diseases have been developed and pursued. However, a major challenge in research is to improve the effectiveness of existing drugs. For this purpose, many avenues and approaches have been explored, but fighting a viral infection remains a challenge, mainly because of the resistance of the virus to existing drugs or vaccines. The establishment of a compatible system and offering a reproducible response are favourable to achieve a well-organised and regulated health system. Permissible medicine "Halalopathy" has been introduced as a new model for building a compatible system between mind, and health system. Halalopathy provides a new approach to preventing disease by managing the entropic state and/or facilitating recovery by implementing the concept of permissible medicine. Halalopathy activates potential by creating a compatible relationship between therapeutic medicines and behaviours that can affect epigenetic traits such as lifestyle. The compatibility sets up a highly ordered system that has reduced entropy and enriched potential energy. Entropy was introduced by halalopathy as an essential element in the prevention and cure of disease. Potential energy dispersion and entropy enrichment can be used to prevent and/or cure COVID-19. The method is based on Le Chatelier's principle and utilises safe and available substances that can be easily taken by most patients. There is potential for the proposed method to reduce COVID-19 to a threshold level that might boost the patient's immune system and enhance recovery.


Dr. Jawad Alzeer is a senior scientist who has completed a PhD in organic chemistry and has worked as a postdoctoral researcher and research associate in various institutions. He has been involved in the discovery of a new HIV inhibitor and has focused on targeted gene therapy and the design of G-quadruplex ligands for cancer therapy. Currently, he is the director of the Swiss Scientific Society for the Developing Countries and a senior researcher at the University of Zurich, where he focuses on linking medicine and chemistry and developing new medical concepts related to prevention and complete recovery.